BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Aptuit, Inc. Names Stuart E. Needleman as President and Chief Operating Officer


3/16/2012 9:34:59 AM

GREENWICH, Conn., March 15, 2012 /PRNewswire/ -- Timothy C. Tyson, Aptuit Chairman, announced that effective immediately, Stuart E. Needleman has been named President and Chief Operating Officer of Aptuit LLC. Following the recent sale of the company's Clinical Trials Supply Business, Mr. Needleman has been promoted from his previous position at Aptuit as President, Scientific Operations. In his new role, Mr. Needleman is responsible for all day-to-day operations of the worldwide Aptuit organization, reporting directly to the company's Board.

(Logo: http://photos.prnewswire.com/prnh/20120217/NY55633LOGO )

In accepting this appointment, Mr. Needleman stated, "I am looking forward to this opportunity to lead the continued growth of Aptuit during the exciting days ahead. I believe that our comprehensive early to mid-phase drug development services, distinguished by our industry leading scientific expertise, are second to none. As we welcome new clients and continue our relationships with those who show their confidence in Aptuit again and again, we are enthusiastic about the future, and we remain dedicated to forging more robust strategic relationships."

In making the announcement, Tim Tyson reported that he will continue in his role as Chairman and will concentrate his efforts on a variety of external growth and strategic partnership opportunities. Mr. Tyson cited Mr. Needleman's recent success as President of Aptuit's Scientific Operations and his substantial industry standing. "Stu is a seasoned veteran with a legacy of more than 30 years of successful sales, marketing and operations experience in drug development services. All of us at Aptuit congratulate him as he leads in building a strong business model based on our solid reputation for scientific excellence."

Mr. Needleman began his career at Cambrex, and previously held senior level, global positions at Oxford Asymmetry, ChiRex, Rhodia Pharma Solutions and Arch Pharmalabs. Mr. Needleman joined Aptuit in 2006 as Vice President, Sales and Marketing, and was later promoted to President of API Development and Manufacturing. In 2011, Mr. Needleman was placed in charge of all the company's scientific efforts as President of Aptuit Scientific Operations. Mr. Needleman earned an MBA and BSc in Chemical Engineering from Rensselaer Polytechnic Institute (RPI).

Stu Needleman resides in Trumbull, CT with his wife and daughter. He is active in numerous local and regional organizations, serving on the Boards of Trumbull Babe Ruth baseball and Trumbull Pisces swimming. Stu and his wife are also active supporters of the Strike 3 Foundation for childhood cancer research.

For more information, please contact Maria Garvey, Delfino Marketing at 914-747-1400 or maria@delfino.com.

Aptuit is a global pharmaceutical services company focusing on delivering contract development and manufacturing services and streamlining the drug development process for biotechnology and pharmaceutical innovators. Aptuit's employees deliver an integrated suite of product development services to more than 800 companies worldwide driven by a deep commitment to client service, quality and an unrivaled track record of scientific excellence. The company is partnered with Welsh, Carson, Anderson & Stowe, one of the world's leading private equity investors. For more information about Aptuit, visit www.aptuit.com

Aptuit: engineering a better drug development process through scientific excellence

SOURCE Aptuit



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES